Adipotide side effects and risks

Reported side effects

• Kidney tubular injury and higher creatinine: Human rate unknown. In lean monkeys at 0.43 mg/kg, creatinine rose sporadically in 2/5., serious. Stop use and seek prompt kidney assessment; symptoms may be absent. (source)
• Potassium and phosphate loss: Dose related changes in monkeys; no human event rates., serious. Check electrolytes and kidney function; do not self-correct with large potassium doses. (source)
• Sugar or protein leaking into urine: Mild–marked urine glucose and mild–moderate protein in monkeys; human rate unknown., serious. Urine testing can reveal injury even when you feel well. (source)
• More urination and dehydration: Observed in monkeys; dehydration was noted at the highest doses., moderate. Prompt assessment for thirst, dizziness or changing urine output. (source)
• Burning, itching, lumps or welts at injection sites: Several online accounts; no denominator or verified human rate., moderate. Persistent or worsening swelling needs clinical review. (source)
• Flushing, fatigue or headache: One online log; no clinical incidence estimate., mild. New or persistent symptoms warrant review rather than dose escalation. (source)
• Reduced appetite: Observed in rodents and monkeys and reported online; human rate unknown., moderate. Track intake and hydration; unexplained rapid weight loss needs assessment. (source)

Stop and get help if

• Much less urine, swollen legs, vomiting, severe thirst or new breathlessness: Stop exposure and seek urgent medical assessment for possible kidney injury.
• New confusion, severe drowsiness, collapse or trouble breathing: Seek emergency care now; do not wait for a routine blood test.
• Swollen tongue or throat, wheezing or fainting after an injection: Call emergency services now for possible severe allergy.
• A new rise in creatinine or new glucose/protein in urine, even without pain: Stop exposure and arrange prompt clinician review; painless injury is possible.

Who should avoid it

• pregnant: Pregnancy safety is unknown. No women were enrolled in the only human trial.
• breastfeeding: Milk transfer and infant safety are unknown; no breastfeeding data were found.
• tryingToConceive: Fertility and embryo safety are unknown. The human trial required contraception.
• under18: The trial excluded anyone under 18; no pediatric safety data were found.
• kidneyDisease: Kidney tubular injury occurred in monkeys. The human trial required adequate kidney function.
• other: Dehydration can worsen kidney injury; adipotide caused urine and electrolyte losses in monkeys.
• other: The trial excluded uncorrected blockage affecting both kidneys or a solitary kidney.
• uncontrolledBloodPressure: The trial excluded chronic uncontrolled blood pressure because of possible existing kidney damage.
• heartCondition: Recent heart attack, unstable angina and severe heart failure were excluded from the human trial.
• liverDisease: The trial excluded chronic liver disease with scarring or impaired liver function.
• diabetes: Uncontrolled diabetes was excluded. Animal glucose changes make medication review important.
• eatingDisorderHistory: Food intake fell in animal studies. With no human safety data, appetite and weight effects are a concern.
• activeCancer: The only human trial involved prostate cancer and has no results. Any use needs oncology review.
• surgeryPlanned: Kidney injury risk warrants review before surgery, fasting or exposure to other kidney-stressing drugs.
• testedAthlete: S0 of the 2026 WADA List covers unapproved substances at all times; this applies to adipotide.

Interactions

• NSAID pain medicines: The trial barred ongoing NSAIDs and required avoidance through 30 days after dosing. Aspirin ≤81 mg/day was excepted; review prescribed aspirin first.
• Strongly kidney-toxic medicines: The trial excluded IV vancomycin, aminoglycosides and other strongly kidney-toxic drugs. Added kidney harm is a concern.
• Insulin and sulfonylureas: Potential low blood sugar if insulin sensitivity or food intake changes. This is an animal-based precaution; no human interaction study exists.
• Diuretics and kidney-sensitive blood-pressure drugs: Fluid loss may increase kidney risk. This is a general kidney precaution, not a measured adipotide interaction; review medicines before changing them.
• Other weight-loss peptides: Stacks are reported online, without controlled combination safety data. Animal kidney harm and reduced intake remain concerns.
• Purported kidney-protection supplements or peptides: Forum users discuss protection, but no adipotide study establishes that these prevent kidney injury.

Product quality risks

• No published test-buy study of online adipotide was found; its real-world purity and dose accuracy are unknown.
• In three online semaglutide samples, purity was 7%–14% and drug content 29%–39% above label. This is indirect evidence, not adipotide testing.
• One semaglutide sample contained 8.95 EU/mg endotoxin despite no viable microbes detected. A sterility result alone misses this risk.
• TGA reports poorly labelled unapproved peptide vials with uncertain ingredients, manufacturing and sterility.